1. Kalaitzidis R, Bakris GL. Optimizing blood pressure and reducing proteinuria. In: Daugirdas J, editor. Handbook of chronic kidney disease management. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 224–39.
2. Study of diabetic nephropathy with atrasentan (SONAR). https://clinicaltrials.gov/ct2/show/NCT01858532 . Accessed 10 Mar 2016.
3. Evaluation of the effects of canagliflozin on renal and cardiovascular outcomes in participants with diabetic nephropathy (CREDENCE). https://clinicaltrials.gov/ct2/show/NCT02065791 . Accessed 10 Mar 2016.
4. Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and diabetic kidney disease (FIDELIO-DKD). https://clinicaltrials.gov/ct2/show/NCT02540993 . Accessed 10 Mar 2016
5. Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015;54:691–708.